TransCode shares surge 20.51% intraday after submitting Phase 2a trial IND amendment with Quantum Leap for colorectal cancer.

TransCode surged 20.51% intraday after submitting an IND amendment for a Phase 2a trial of TTX-MC138 in colorectal cancer with Quantum Leap Healthcare Collaborative. The trial, part of the PRE-I-SPY platform, targets minimal residual disease post-curative therapy and aims to begin in H1 2026. This advancement underscores TransCode’s strategic expansion into colorectal cancer research and validates its MRD-targeting approach, positioning TTX-MC138 as a potential breakthrough in immuno-oncology. The partnership with Quantum Leap and the trial’s focus on ctDNA-positive patients highlight the company’s progress in leveraging RNA therapeutics for high-risk cancers, driving investor optimism.